Creative Planning Cybin Inc. Transaction History

Creative Planning

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	BUY	$0.26 - $0.46 $260 - $460	1,000 Added 5.8%	18,251 $4,000
Q1 2024 May 10, 2024	SELL	$0.3 - $0.46 $2,628 - $4,030	-8,761 Reduced 33.68%	17,251 $7,000
Q4 2023 Feb 14, 2024	BUY	$0.38 - $0.65 $2,376 - $4,065	6,255 Added 31.66%	26,012 $10,000
Q3 2023 Nov 16, 2023	BUY	$0.29 - $0.63 $2,552 - $5,544	8,800 Added 80.31%	19,757 $10,000
Q1 2023 May 15, 2023	SELL	$0.3 - $0.56 $300 - $560	-1,000 Reduced 8.36%	10,957 $4,000
Q4 2022 Feb 10, 2023	SELL	$0.26 - $0.64 $91 - $224	-350 Reduced 2.84%	11,957 $3,000
Q3 2022 Nov 03, 2022	SELL	$0.48 - $1.11 $480 - $1,110	-1,000 Reduced 7.51%	12,307 $6,000
Q2 2022 Aug 15, 2022	SELL	$0.41 - $0.88 $142 - $305	-347 Reduced 2.54%	13,307 $7,000
Q1 2022 May 16, 2022	SELL	$0.74 - $1.22 $404 - $667	-547 Reduced 3.85%	13,654 $11,000
Q4 2021 Feb 11, 2022	SELL	$1.13 - $2.31 $111 - $228	-99 Reduced 0.69%	14,201 $17,000
Q3 2021 Nov 10, 2021	BUY	$1.83 - $3.18 $26,169 - $45,474	14,300 New	14,300 $31,000

185K

Ticker CYBN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 166,120,000
Market Cap $2.07B
Description
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to t...

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

Stay updated on Creative Planning with notifications on news.